In Western countries, prostate cancer is the most prevalent cancer of men and one of the leading causes of cancer-related death in men. Several genome-wide association studies have yielded numerous common variants conferring risk of prostate cancer. Here, we analyzed 32.5 million variants discovered by whole-genome sequencing 1,795 Icelanders. We identified a new low-frequency variant at 8q24 associated with prostate cancer in European populations, rs188140481[A] (odds ratio (OR) = 2.90; P combined = 6.2 × 10 −34 ), with an average risk allele frequency in controls of 0.54%. This variant is only very weakly correlated (r 2 ≤ 0.06) with previously reported risk variants at 8q24, and its association remains significant after adjustment for all known risk-associated variants. Carriers of rs188140481 [A] were diagnosed with prostate cancer 1.26 years younger than non-carriers (P = 0.0059). We also report results for a previously described HOXB13 variant (rs138213197[T]), confirming it as a prostate cancer risk variant in populations from across Europe.
Risk of prostate cancer has been shown to have a strong genetic component 1, 2 . Numerous genome-wide association studies (GWAS) are registered in the Catalog of Published Genome-Wide Association Studies (see URLs), where well over 40 prostate cancer susceptibility loci are listed. However, these risk variants, which were discovered using commercial genotyping chips, are common, and each confers moderate-to-low risk. New high-throughput whole-genome sequencing techniques allow for the systematic search for rarer risk variants that possibly also confer greater risk. An example of such a variant is the recently published missense SNP in HOXB13 conferring high risk of prostate cancer 3 . Here, we report one additional independent variant located at 8q24 that is rarer and confers greater risk than previously published common prostate cancer risk variants.
To search for prostate cancer risk variants, we analyzed data generated by the ongoing whole-genome sequencing project at deCODE genetics. In short, the goal of this project is to sequence 2,500 Icelanders to at least tenfold coverage of the genome for each individual. The variants (SNPs and insertions and/or deletions (indels)) discovered in the sequencing phase are then propagated into chipgenotyped individuals, as well as into individuals without genotypic information, making use of the extensive genealogical information available in Iceland as well as phasing and imputation methods previously described 4 . At the time that the association analysis in our study was performed, 1,795 Icelanders had been sequenced to at least tenfold coverage. The approximately 32.5 million variants discovered through whole-genome sequencing were imputed into 71,743 Icelanders who had all been genotyped using commercial Illumina SNP chips, as well as into 296,496 Icelanders without direct chip genotypes but with family-based imputation genotype information 4, 5 (Online Methods and Supplementary Note). Our list of individuals with prostate cancer (cases) includes 5,141 men diagnosed from 1955 to the end of 2010, according to the nationwide Icelandic Cancer Registry (ICR; see URLs). Of these cases, 2,315 had been genotyped using an Illumina chip, and 2,222 additional cases had at least partial genotype data from family-based imputation, leaving 604 of the list of all cases with no genotypic information. As controls, we used 54,444 males (27,780 had variants imputed on the basis of chip genotypes, and 26,664 had variants imputed with family-based methods; Supplementary Note) not diagnosed with prostate cancer according to the nationwide ICR.
According to our analysis, 252 variants were significantly associated with prostate cancer at P < 1.5 × 10 −9 (a GWAS significance threshold applicable according to a Bonferroni correction for 32 million tests). All these variants were located at the previously described prostate cancer risk loci at 8q24 and 17q12. To search for new risk variants at these two loci, we used multivariate logistic regression analysis.
When analyzing the 17q12 locus, we adjusted for the variant rs4430796, the SNP originally reported at this locus 6 that was also most significantly associated with prostate cancer at this locus in our present GWAS. In this conditional analysis, no other variant at 17q12 had an association signal that remained significant at our GWAS P-value threshold.
At the 8q24 locus, nine independent prostate cancer risk variants have previously been published [7] [8] [9] [10] [11] [12] [13] [14] (Supplementary Table 1a ). These variants are distributed over five neighboring linkage disequilibrium (LD) blocks (Fig. 1) . When performing the multivariate logistic regression analysis for the variants at 8q24 in our current GWAS, we first adjusted for the SNP most significantly associated with prostate cancer, which was rs11995378, located in region 1 (r 2 = 0.95 between rs11995378 and rs1447295, the SNP originally reported 7 in region 1). In the second step, we conditioned on two SNPs, including the SNP used in step 1 as well as the SNP with the most significant association after step 1, rs77541621, located in region 2 (r 2 = 0.64 between rs77541621 and rs16901979, the SNP initially reported 8, 10 in region 2). On the basis of the results from step 2, four SNPs and one indel, all correlated with each other (r 2 ≥ 0.74; Supplementary Table 1b), remained significant at the GWAS P-value threshold. Of these, in the unconditional familybased imputed results, the most significant association with prostate cancer was observed for the minor allele (the G allele) of rs183373024 (P = 1.50 × 10 −23 ; OR = 2.69) and the minor allele (the A allele) of rs188140481 (P = 1.5 × 10 −22 ; OR = 2.88). In the third step of the logistic regression analysis, after adding rs183373024 to the list of SNPs on which association was conditioned, no variant remained significant at the applicable P-value threshold of P < 1.5 × 10 −9 ( Fig. 1) Build 36 ) at 8q24. Green triangles denote imputed association results from the unconditional analysis. Purple crosses denote association results after step 1 of the conditional analysis (logistic regression), red boxes denote association results after step 2, and orange circles denote association result after step 3. The red diamonds below the x axis represent the previously reported prostate cancer risk SNPs at 8q24 in populations of European descent (1, rs12543663; 2, rs10086908; 3, rs1016343; 4, rs13252298; 5, rs16901979; 6, rs16902094; 7, rs445114/rs620861; 8, rs6983267; 9, rs1447295), and the two blue diamonds represent the two SNPs (A, rs183373024; B, rs188140481) tagging the association signals discussed in the main text. (b) Shown are the Utah residents of Northern and Western European ancestry (CEU) HapMap population recombination rate and the pairwise correlation coefficient (r 2 ) for SNPs in the 1-Mb region depicted. The annotations of LD blocks and regions are as previously described [7] [8] [9] 14, 21 . Shown are association results (allelic OR with 95% confidence interval (CI) and P value) for rs188140481. All P values shown are two sided. The P value for the heterogeneity of the ORs (P het ) for all study groups was 0.88, and I 2 , which lies between 0% and 100% and describes the proportion of total variation in study estimates that is due to heterogeneity, was 0.0%. For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, whereas ORs and P values were estimated using the Mantel-Haenszel model. Of the Icelandic cases, 2,315 had been genotyped using an Illumina chip, and 2,222 additional cases had at least partial genotype information from family-based imputation. Of the Icelandic controls, 27,780 were imputed on the basis of chip genotypes, and 26,664 underwent family-based imputation. All non-Icelandic replication samples were directly genotyped.
l e t t e r s npg l e t t e r s
Of the previously published prostate cancer risk SNPs located at 8q24 that were not included among or were not strongly correlated with the SNPs on which association was conditioned in the logistic regression analysis, four remained marginally significant (P < 0.05): rs13252298, rs16902094, rs445114 and rs6983267 (Supplementary Table 2 ).
To validate the Icelandic association results, we genotyped rs183373024 and rs188140481 in five prostate cancer study groups including individuals of European descent. These groups come from The Netherlands, Spain, Romania, the UK and the United States. The combined results of the five study groups showed significant associations for both SNPs, and combining them with the imputed results from Iceland gave an estimated OR of 2.59 for rs183373024 [G] (P combined = 4.1 × 10 −33 ) and an OR of 2.90 for rs188140481 [A] (P combined = 6.2 × 10 −34 ). The frequencies of the risk alleles of these two variants in controls ranged from 0.1-1.1% and were lowest in Southern Europe and higher in Northern Europe. A test of heterogeneity among all six study groups showed no significant difference between the ORs of the two variants (P het > 0.32; Table 1 and Supplementary Table 3) . We also genotyped both SNPs in 498 Asian prostate cancer cases from Hong Kong and 467 African-American controls from Chicago, but the SNPs were not polymorphic in these study groups. Hence, if the underlying causative risk variant is present in these two ancestry groups, it is either not tagged by these SNPs or is very rare.
Because the association effects of the two variants cannot be distinguished from each other, we elected to focus on rs188140481[A] in subsequent investigations, on the basis of its slightly stronger combined replication results relative to rs183373024. Neither rs188140481 nor any of the highly correlated variants (r 2 > 0.7; Supplementary Table 1b) are present in the latest HapMap release (data release 28). Therefore, association analysis based on HapMap data did not yield the association signal reported here. The rs188140481 SNP is, however, in the 1000 Genomes Project data set registered into the dbSNP135 database in July 2011.
The rs188140481 SNP is located telomeric to the previously published region 2 at 8q24, originally reported to contain the prostate cancer risk SNP rs16901979 (ref. 8) and, later, also rs1016343 and rs13252298 (ref. 14) (Fig. 1) . rs188140481 is in strong LD (D′ = 1) with those three SNPs, but it is only very weakly correlated with them (r 2 ≤ 0.005). Furthermore, the correlation (the r coefficient) between rs188140481 and rs16901979 is in a negative direction. Of the previously published risk SNPs in populations of European descent that are located at 8q24, rs16901979 has the closest resemblance to rs188140481 in terms of conferred risk and allele frequency (risk allele control frequency in Iceland is ~3% and ~1% for rs16901979[A] and rs188140481[A], respectively). This indicates that the two risk variants are never together on the same haplotype. Consequently, the association results for rs16901979 and rs188140481 remained significant after being adjusted for each other. Furthermore, rs188140481 is only very weakly correlated (r 2 < 0.06) with the previously published leukemia 15 , prostate cancer [7] [8] [9] [10] 14 , colon cancer [16] [17] [18] , breast cancer 19 and bladder cancer 20 risk variants at 8q24 (Supplementary Table 1a) , and the association results for rs188140481 remained significant after being adjusted for all nine previously published prostate cancer risk SNPs at 8q24 ( Table 2) .
We examined rs188140481 and the four correlated variants (r 2 > 0.7) for known functional features in the Encyclopedia of DNA Elements (ENCODE) project. We noted that rs183373024 is located at a site of DNase I hypersensitivity in prostate adenocarcinoma and normal prostate cell lines (LNCaP and PrEC, respectively; Supplementary  Fig. 1 ).Whether this has any biological consequences remains to be studied further. Other correlated variants were not found at sites predicted to have a biological effect.
Recently, a rare missense variant (rs138213197[T], encoding p.Gly84Glu) in HOXB13 was found to confer risk of prostate cancer in a US study population 3 . To assess the HOXB13 association signal in study populations independent of that reported in the original study, we genotyped rs138213197 in five study groups of European descent. Combination of the imputed Icelandic results and the results from the five directly genotyped replication study groups gave an estimated OR of 7.06 (P combined = 1.5 × 10 −19 ; Table 3 ). This effect is comparable but somewhat lower than the effect reported in the initial study 3 . We also genotyped rs138213197 in 498 Asian prostate cancer cases from Hong Kong and 467 African-American controls from Chicago, but we did not detect the risk allele in these individuals, suggesting that either the risk variant is very rare or is not present in these two ancestry groups.
To further analyze the new variant at 8q24 and the HOXB13 variant, we stratified the prostate cancer cases from the six study groups of European descent according to age at diagnosis and aggressiveness of the disease. For rs188140481[A] at 8q24, when comparing the group of cases with more aggressive phenotypes (having at least one of the Shown are the association results (allelic OR with 95% CI and P value) for rs138213197. All P values shown are two sided. P het for all study groups was 0.36, and I 2 was 8.6%. For the combined study populations, the reported control frequency was the average, unweighted control frequency of the individual populations, and ORs and P values were estimated using the MantelHaenszel model. Of the Icelandic cases, 2,315 had been genotyped using an Illumina chip, and 2,222 additional cases had at least partial genotype information from family-based imputation. Of the Icelandic controls, 27,780 were imputed on the basis of chip genotypes, and 26,664 underwent family-based imputation. All non-Icelandic replication samples were directly genotyped. Shown are association results (allelic OR with 95% CI and P value) for rs188140481 adjusted and unadjusted for the nine previously published anchor prostate cancer risk SNPs in populations of European descent located at 8q24 (rs12543663, rs10086908, rs1016343, rs13252298, rs16901979, rs16902094, rs445114/rs620861, rs6983267 and rs1447295). Only individuals directly genotyped at rs188140481 were used in this analysis. For the adjusted analysis, P het = 0.89, I 2 = 0.0%; for the unadjusted analysis, P het = 0.81, I 2 = 0.0%.
npg l e t t e r s Table 5b ).
When examining the genotypic status of all subjects in our study, one subject was found to be homozygous for the HOXB13 variant: a Dutch prostate cancer case diagnosed at the age of 69 with a positive family history of prostate cancer (two brothers diagnosed at the ages of 67 and 74; no DNA samples were available from these individuals). In the Icelandic study group, we identified 13 Icelandic male carriers of the HOXB13 variant who have been diagnosed with prostate cancer. Of these, four have a positive family history of prostate cancer: two belong to a brother pair, and two belong to a father-offspring pair. The remaining nine cases do not have any first-or second-degree male relatives diagnosed with prostate cancer, according to the extensive genealogy database at deCODE genetics and the nationwide ICR database.
We identified 16 homozygous carriers of the 8q24 variant: a Dutch prostate cancer case diagnosed at the age of 69 and not known to have a positive family history of prostate cancer, 8 Icelandic females and 7 Icelandic males. Of the seven Icelandic males, five have been diagnosed with prostate cancer (ages at diagnosis ranged between 55 and 87 years), and the remaining two were both born in 1953 (age at the time of the study of 59 years) and are not known to have been diagnosed with prostate cancer. The five Icelandic homozygous prostate cancer cases (of whom four belong to two brother pairs) all have one or more close relatives within the nuclear family diagnosed with prostate cancer (Supplementary Fig. 2 ). This shows a high prevalence of the disease among homozygous male carriers over 60 years of age. Furthermore, using directly generated genotypes only, the carrier frequency among Icelandic cases with a positive family history was estimated to be 10.9% compared to 4.2% among cases without a family history (OR = 2.70; P = 1.8 × 10 −5 ).
In summary, we have discovered a new independent prostate cancer risk variant at the 8q24 locus. The risk profile of this new variant differs from other risk variants discovered by GWAS in being rare and conferring greater risk of the disease. In addition, the replication results for the HOXB13 coding variant presented here confirm that it is a prostate cancer risk variant in populations from across Europe.
URLs. Catalog of Published Genome-Wide Association Studies, http://www.genome.gov/gwastudies/; Icelandic Cancer Registry (ICR), http://www.krabbameinsskra.is/indexen.jsp?icd=C61.
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Study populations. Written informed consent was obtained from all study participants, and the study has been approved by the National Bioethics Committee of Iceland. A description of the study populations is provided in the Supplementary Note. Genotyping methods. Illumina genome-wide genotyping. The Icelandic chipgenotyped samples were assayed with the Illumina Human Hap300, Hap CNV370, Hap 610, 1M or Omni-1 Quad BeadChips at deCODE genetics. SNPs were excluded if they had (i) yield of less than 95%, (ii) minor allele frequency of less than 1% in the population or (iii) significant deviation from Hardy-Weinberg equilibrium in the controls (P < 0.001), (iv) if they produced an excessive inheritance error rate (over 0.001) or (v) if there was substantial difference in allele frequency between chip genotypes (from just a single chip if that resolved all differences, but from all chips otherwise). All samples with a call rate below 97% were excluded from the analysis. The final set of SNPs used for long-range phasing was composed of 785,863 SNPs.
Single-track assay SNP genotyping. Genotyping of the SNPs reported in Tables 1-3 for the five case-control groups from The Netherlands, Spain, Romania, the UK and the United States was carried out by deCODE genetics in Reykjavik, Iceland, applying the Centaurus 22 (Nanogen) platform. Using the Centaurus single-track assay, we genotyped all cases and controls available from these study populations. To confirm the imputed Icelandic association results for rs188140481 at 8q24 and rs138213197 in HOXB13, we directly genotyped over 3,900 Icelandic study subjects using the Centaurus single-track assay for these SNPs. The correlation (r 2 ) between the results of two genotyping methods for these two SNPs was >0.94.
Sanger sequencing. To confirm the genotypes from Centaurus single-track assay genotyping, using standard procedure, we performed Sanger sequencing of all carriers of the HOXB13 variant identified in all the study populations as well as all homozygous carriers and 25 heterozygous Icelandic carriers of the 8q24 variant rs188140481. The concordance rate between the different genotyping platforms was above 98%.
Whole-genome sequencing and SNP imputation. Of the 1,795 individuals on whom whole-genome sequencing was performed and used in the current study, 53 have been diagnosed with prostate cancer according to the nationwide list maintained by the ICR. A more detailed description of the key steps of wholegenome sequencing and imputation is provided in the Supplementary Note.
Bioinformatics. For the list of SNPs correlated with rs188140481, we carried out a search for overlap between SNP position and known bioinformatic features. We retrieved data from the UCSC test browser (hg19 Build 37). We accessed all feature tracks relevant to prostate tissue as well as containing genome positional information and identified those features that overlapped with the SNPs. These are recognized draft-quality data and were used as is, without quality filtering.
Statistical analysis.
Long -/-range phasing. Long -/-range phasing of all chipgenotyped individuals was performed with methods described previously 4, [23] [24] [25] [26] . In brief, phasing is achieved using an iterative algorithm that phases a single proband at a time given the available phasing information about everyone else that shares a long haplotype identical by state with that of the proband. Given the large fraction of the Icelandic population that has been chip genotyped, accurate longrange phasing is available across the genome for all chip-genotyped Icelanders.
Genotype imputation. We imputed the SNPs identified and genotyped through sequencing into all Icelanders who had been phased with long-range phasing, using the same model as used by IMPUTE 27 (a more detailed description is provided in the Supplementary Note).
In silico genotyping. In addition to imputing sequence variants from the whole-genome sequencing effort into chip-genotyped individuals, we also performed a second imputation step where genotypes were imputed into the relatives of chip-genotyped individuals, creating in silico genotypes. The input for the second imputation step was the fully phased imputed and chip-derived genotypes of the available chip-genotyped individuals (in particular, every allele has been assigned a parent of origin; a detailed description is provided in the Supplementary Note).
Genotype imputation information. The informativeness of genotype imputation was estimated by the ratio of the variance of imputed expected allele counts and the variance of the actual allele counts. For the present study, when imputed genotypes were used, the information value for all SNPs was between 0.92 and 0.99.
Case-control association testing. Logistic regression analysis was used to test for association between SNPs and disease, treating disease status as the response and expected genotype counts from imputation or allele counts from direct genotyping as covariates. Testing was performed using the likelihood ratio statistic (detailed descriptions of the genotyping, sequencing and statistical methods are provided in the Supplementary Note and refs. [24] [25] [26] .
Multivariate logistic regression. For this analysis, we only used cases and controls who had been genotyped using the Illumina chip genotyping platform. The multivariate logistic regression analysis was performed conditioning for a given marker by adjusting for the estimated allele count on the basis of imputation of this marker. The genomic control correction factor was the same as used for the unadjusted association analysis. A forward selection multiple logistic regression model was used to further define the extent of the genetic association. Briefly, all imputed SNPs located within the interval 127.8 Mb to 128.8 at 8q24 were tested for possible incorporation into a multiple-regression model. In stepwise fashion, a SNP was added to the model if it had the smallest P value among all SNPs not yet included in the model and if it had a P value below 1.5 × 10 −9 (a GWAS significance threshold applicable according to a Bonferroni correction for 32 million tests). In the last step, none of the SNPs remained significant at this threshold.
Inflation factor adjustment. To account for the relatedness and stratification within our case and control sample sets, we applied the method of genomic control based on chip markers. For prostate cancer GWAS, the correction factor based on the genomic control was 1.33.
